Reistone Biopharma Company Limited

Quick facts

Phase 2 pipeline

• Drug: SHR0302 · Diabetes
  SHR0302 is a small molecule that targets the SGLT2 receptor.
• Drug - SHR1459
• RSS0343 tablets
• SHR1459 High Dose
• SHR1459 Low Dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Reistone Biopharma Company Limited portfolio CI brief
• Reistone Biopharma Company Limited pipeline updates RSS

Related

• Sector hub: All tracked pharma companies